5lhq
From Proteopedia
(Difference between revisions)
(2 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | The | + | ==The EGR-cmk active site inhibited catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7== |
+ | <StructureSection load='5lhq' size='340' side='right'caption='[[5lhq]], [[Resolution|resolution]] 2.60Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[5lhq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [https://en.wikipedia.org/wiki/Vicugna_pacos Vicugna pacos]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5LHQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5LHQ FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.6Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=0GJ:L-ALPHA-GLUTAMYL-N-{(1S)-4-{[AMINO(IMINIO)METHYL]AMINO}-1-[(1S)-2-CHLORO-1-HYDROXYETHYL]BUTYL}GLYCINAMIDE'>0GJ</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5lhq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5lhq OCA], [https://pdbe.org/5lhq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5lhq RCSB], [https://www.ebi.ac.uk/pdbsum/5lhq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5lhq ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/UROK_MOUSE UROK_MOUSE] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Although trypsin-like serine proteases have flexible surface-exposed loops and are known to adopt higher and lower activity conformations, structural determinants for the different conformations have remained largely obscure. The trypsin-like serine protease, urokinase-type plasminogen activator (uPA), is central in tissue remodeling processes and also strongly implicated in tumor metastasis. We solved five X-ray crystal structures of murine uPA (muPA) in the absence and presence of allosteric molecules and/or substrate-like molecules. The structure of unbound muPA revealed an unsuspected non-chymotrypsin-like protease conformation in which two beta-strands in the core of the protease domain undergoes a major antiparallel-to-parallel conformational transition. We next isolated two anti-muPA nanobodies; an active-site binding nanobody and an allosteric nanobody. Crystal structures of the muPA:nanobody complexes and hydrogen-deuterium exchange mass spectrometry revealed molecular insights about molecular factors controlling the antiparallel-to-parallel equilibrium in muPA. Together with muPA activity assays, the data provide valuable insights into regulatory mechanisms and conformational flexibility of uPA and trypsin-like serine proteases in general. | ||
- | + | Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.,Kromann-Hansen T, Louise Lange E, Peter Sorensen H, Hassanzadeh-Ghassabeh G, Huang M, Jensen JK, Muyldermans S, Declerck PJ, Komives EA, Andreasen PA Sci Rep. 2017 Jun 13;7(1):3385. doi: 10.1038/s41598-017-03457-7. PMID:28611361<ref>PMID:28611361</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 5lhq" style="background-color:#fffaf0;"></div> |
- | [[Category: | + | |
- | [[Category: | + | ==See Also== |
- | [[Category: Declerck | + | *[[Antibody 3D structures|Antibody 3D structures]] |
- | [[Category: Ghassabeh | + | *[[Plasminogen activator|Plasminogen activator]] |
- | [[Category: | + | *[[Urokinase 3D Structures|Urokinase 3D Structures]] |
- | [[Category: Jensen | + | *[[3D structures of non-human antibody|3D structures of non-human antibody]] |
- | [[Category: Kromann-Hansen | + | == References == |
- | [[Category: | + | <references/> |
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Large Structures]] | ||
+ | [[Category: Mus musculus]] | ||
+ | [[Category: Vicugna pacos]] | ||
+ | [[Category: Andreasen PA]] | ||
+ | [[Category: Declerck PJ]] | ||
+ | [[Category: Ghassabeh GH]] | ||
+ | [[Category: Huang M]] | ||
+ | [[Category: Jensen JK]] | ||
+ | [[Category: Kromann-Hansen T]] | ||
+ | [[Category: Lange EL]] | ||
+ | [[Category: Muyldermans S]] | ||
+ | [[Category: Sorensen HP]] |
Current revision
The EGR-cmk active site inhibited catalytic domain of murine urokinase-type plasminogen activator in complex with the allosteric inhibitory nanobody Nb7
|